Kite Pharma(KITE)高管介绍_美股行情_同花顺金融网

来自 : stockpage.10jqka.com.cn/KITE/m 发布时间：2021-03-26

Arie Belldegrun,本公司的创始人、执行董事长。2014年3月，他还被任命为本公司的总裁、首席执行官，这是一个临时性的职位，他从2013年12月担任该职务。2008年3月至今，他担任生物制药公司Arno Therapeutics的董事长；2012年12月至今，担任制药公司TheraCoat Ltd.的董事长；2009年6月至今，担任咨询公司River Consulting LLC的董事长、合伙人；2009年10月至今，担任保健公司 SonaCare Medical的董事；自2013年3月至今，担任制药公司Teva Pharmaceutical Industries 的董事。2009年9月至2013年11月，他担任生物技术公司 Nile Therapeutics的董事。1996年，他创办生物技术公司Agensys，在1996-2001年间担任创始董事长，并一直担任董事直到2007年它被Astellas Pharma 收购。他还从2003年起，担任生物技术公司 Cougar Biotechnology的创始副董事长、及其科学顾问委员会的主席，直到2009年它被Johnson & Johnson收购。他获得了American Board of Urology的专业认证，并且是American College of Surgeons 和 American Association of Genitourinary Surgeons的资深会员。他是一名泌尿外科教授，也是 David Geffen School of Medicine at the University of California, Los Angeles（UCLA）的泌尿外科肿瘤学Roy and Carol Doumani主席、泌尿外科肿瘤研究所所长。1988年10月加入UCLA之前，1985年7月至1988年8月，他在 NCI/NIH 从事外科肿瘤学和免疫疗法研究，是Dr. Steven A. Rosenberg下属的研究员。他在耶路撒冷的Hebrew University Hadassah Medical School 获得医学博士学位，在Weizmann Institute of Science 完成免疫学研究生课程的学习，并在 Harvard Medical School完成泌尿外科的住院实习。

Arie Belldegrun is one of our founders and has served as Chairman of our board of directors since November 2017. Dr. Belldegrun is a co-founder of Allogene Therapeutics, Inc., a public biopharmaceutical company, and has served as Executive Chairman of its board of directors since November 2017. From March 2014 until October 2017 Dr. Belldegrun served as the President and Chief Executive Officer of Kite Pharma, Inc. and as a member of its board of directors from June 2009 until its acquisition by Gilead in October 2017. Dr. Belldegrun currently serves as Chairman of UroGen Pharma Ltd., a position he has held since December 2012 as Chairman and Partner of Two River Consulting, LLC, a life-science consulting and investment firm, a position he has held since June 2009 as a director of Breakthrough Properties LLC and Breakthrough Services LLC, a position he has held since April 2019 and as a director of ByHeart, Inc., a position he has held since October 2019. Dr. Belldegrun has also served as Senior Managing Director of Vida Ventures, LLC since November 2017. Dr. Belldegrun previously served as a director of Teva Pharmaceutical Industries Ltd. from March 2013 until January 2017 Chairman of Arno Therapeutics, Inc. from March 2008 until January 2017 a director of Capricor Therapeutics, Inc. from September 2009 until November 2013 and a director of SonaCare Medical, LLC from October 2009 until October 2014. In 1996 he founded Agensys, Inc., a biotechnology company, where he served as its founding Chairman from 1996 to 2001 and continued to serve on its board of directors until 2007 when it was acquired by Astellas Pharma Inc. Dr. Belldegrun was also the Founding Vice-Chairman of the board of directors and Chairman of the scientific advisory board of Cougar Biotechnology, Inc., a biotechnology company, from 2003 to 2009 when it was acquired by Johnson & Johnson. He is certified by the American Board of Urology and is a Fellow of the American College of Surgeons and the American Association of Genitourinary Surgeons. Dr. Belldegrun is Professor of Urology, holds the Roy and Carol Doumani Chair in Urologic Oncology, and Director of the Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. Prior to joining UCLA in October of 1988 he was a research fellow at NCI/NIH in surgical oncology and immunotherapy from July 1985 to August 1988 under Dr. Steven Rosenberg. Dr. Belldegrun received his M.D. from the Hebrew University Hadassah Medical School in Jerusalem before completing his post graduate studies in Immunology at the Weizmann Institute of Science and his residency in Urologic Surgery at Harvard Medical School. Arie Belldegrun,本公司的创始人、执行董事长。2014年3月，他还被任命为本公司的总裁、首席执行官，这是一个临时性的职位，他从2013年12月担任该职务。2008年3月至今，他担任生物制药公司Arno Therapeutics的董事长；2012年12月至今，担任制药公司TheraCoat Ltd.的董事长；2009年6月至今，担任咨询公司River Consulting LLC的董事长、合伙人；2009年10月至今，担任保健公司 SonaCare Medical的董事；自2013年3月至今，担任制药公司Teva Pharmaceutical Industries 的董事。2009年9月至2013年11月，他担任生物技术公司 Nile Therapeutics的董事。1996年，他创办生物技术公司Agensys，在1996-2001年间担任创始董事长，并一直担任董事直到2007年它被Astellas Pharma 收购。他还从2003年起，担任生物技术公司 Cougar Biotechnology的创始副董事长、及其科学顾问委员会的主席，直到2009年它被Johnson & Johnson收购。他获得了American Board of Urology的专业认证，并且是American College of Surgeons 和 American Association of Genitourinary Surgeons的资深会员。他是一名泌尿外科教授，也是 David Geffen School of Medicine at the University of California, Los Angeles（UCLA）的泌尿外科肿瘤学Roy and Carol Doumani主席、泌尿外科肿瘤研究所所长。1988年10月加入UCLA之前，1985年7月至1988年8月，他在 NCI/NIH 从事外科肿瘤学和免疫疗法研究，是Dr. Steven A. Rosenberg下属的研究员。他在耶路撒冷的Hebrew University Hadassah Medical School 获得医学博士学位，在Weizmann Institute of Science 完成免疫学研究生课程的学习，并在 Harvard Medical School完成泌尿外科的住院实习。 Arie Belldegrun is one of our founders and has served as Chairman of our board of directors since November 2017. Dr. Belldegrun is a co-founder of Allogene Therapeutics, Inc., a public biopharmaceutical company, and has served as Executive Chairman of its board of directors since November 2017. From March 2014 until October 2017 Dr. Belldegrun served as the President and Chief Executive Officer of Kite Pharma, Inc. and as a member of its board of directors from June 2009 until its acquisition by Gilead in October 2017. Dr. Belldegrun currently serves as Chairman of UroGen Pharma Ltd., a position he has held since December 2012 as Chairman and Partner of Two River Consulting, LLC, a life-science consulting and investment firm, a position he has held since June 2009 as a director of Breakthrough Properties LLC and Breakthrough Services LLC, a position he has held since April 2019 and as a director of ByHeart, Inc., a position he has held since October 2019. Dr. Belldegrun has also served as Senior Managing Director of Vida Ventures, LLC since November 2017. Dr. Belldegrun previously served as a director of Teva Pharmaceutical Industries Ltd. from March 2013 until January 2017 Chairman of Arno Therapeutics, Inc. from March 2008 until January 2017 a director of Capricor Therapeutics, Inc. from September 2009 until November 2013 and a director of SonaCare Medical, LLC from October 2009 until October 2014. In 1996 he founded Agensys, Inc., a biotechnology company, where he served as its founding Chairman from 1996 to 2001 and continued to serve on its board of directors until 2007 when it was acquired by Astellas Pharma Inc. Dr. Belldegrun was also the Founding Vice-Chairman of the board of directors and Chairman of the scientific advisory board of Cougar Biotechnology, Inc., a biotechnology company, from 2003 to 2009 when it was acquired by Johnson & Johnson. He is certified by the American Board of Urology and is a Fellow of the American College of Surgeons and the American Association of Genitourinary Surgeons. Dr. Belldegrun is Professor of Urology, holds the Roy and Carol Doumani Chair in Urologic Oncology, and Director of the Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. Prior to joining UCLA in October of 1988 he was a research fellow at NCI/NIH in surgical oncology and immunotherapy from July 1985 to August 1988 under Dr. Steven Rosenberg. Dr. Belldegrun received his M.D. from the Hebrew University Hadassah Medical School in Jerusalem before completing his post graduate studies in Immunology at the Weizmann Institute of Science and his residency in Urologic Surgery at Harvard Medical School.